Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.

@article{Schaerer2015ProteaseIT,
  title={Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.},
  author={V Schaerer and Sebastian Haubitz and Helen Kovari and Bruno Ledergerber and Juan C Ambrosioni and Matthias Cavassini and Marcel P Stoeckle and Patrick Schmid and Laurent A Decosterd and Manel Aouri and J{\"u}rg B{\"o}ni and Huldrych F. G{\"u}nthard and Hansjakob Furrer and Karin J. Metzner and Jan Sven Fehr and Andri Rauch},
  journal={HIV medicine},
  year={2015},
  volume={16 10},
  pages={599-607}
}
OBJECTIVES Direct-acting antiviral agents (DAAs) have become the standard of care for the treatment of chronic hepatitis C virus (HCV) infection. We aimed to assess treatment uptake and efficacy in routine clinical settings among HIV/HCV coinfected patients after the introduction of the first generation DAAs. METHODS Data on all Swiss HIV Cohort Study (SHCS) participants starting HCV protease inhibitor (PI) treatment between September 2011 and August 2013 were collected prospectively. The… CONTINUE READING